GSK wins FDA approval for Hibsago, a first-in-class hepatitis B therapy. Learn how this and a new Jemperli indication shape the company’s specialty growth outlook.

Human interprets the integral and transversal training model of the Campus Bio-Medico University of Rome, which combines scientific preparation, a multidisciplinary approach, and attention to the ...

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

For long-term growth, GSK has several promising pipeline candidates. GSK is increasing R&D investment in promising new ...

Today, in Bagnoli, it's not just the first AC75 of the French team La Roche-Posay that's hitting the water: a new idea of the future is setting sail. Here, after decades of missed opportunities, ...

Spero Therapeutics' CEO Esther Rajavelu will attend the Chardan Healthcare Conference, but the event itself holds no new ...

Get latest articles and stories on Business at LatestLY. India and Southeast Asia stand out as the most growth-oriented ...

GSK's ViiV Healthcare reports Cabenuva's superior viral suppression in HIV, and the company advances key acquisitions and ...

The Philadelphia Business Journal reported on October 9th on GSK’s announcement that it is adding a “nextgen flex factory” to ...

UK stocks have significantly high dividend yields than U.S. stocks and offer a good alternative for investors looking to diversity. .

GSK already has a liver-focused siRNA candidate in the clinic in the form of gatuzosiran. (Sheldon Cooper/SOPA Images/LightRocket via Getty Images) GSK is paying Wave Life Sciences $12 million upfront ...